Alpine Immune Sciences, Inc

(NASDAQ:ALPN)

Latest On Alpine Immune Sciences, Inc (ALPN):

Date/Time Type Description Signal Details
2023-05-12 06:01 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.28 beats by $0.09, revenue of $9.4M beats by $2.52MN/A
2023-03-29 08:50 ESTNewsAlpine Immune: Rebuilding Itself From Scratch, But Long Way To Go Before ProofN/A
2023-03-24 06:33 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.41 misses by $0.14, revenue of $2.78M misses by $8.18MN/A
2023-03-24 06:33 ESTNewsAlpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Call TranscriptN/A
2023-03-22 23:18 ESTNewsAlpine Immune Sciences Q4 2022 Earnings PreviewN/A
2023-01-19 15:46 ESTNewsAlpine Immune wins bullish views at Morgan Stanley on lead programN/A
2022-11-14 22:08 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.42 misses by $0.32, revenue of $8.37M misses by $10.31MN/A
2022-11-14 22:08 ESTNewsAlpine Immune Sciences, Inc. (ALPN) Q3 2022 Earnings Call TranscriptN/A
2022-11-12 00:39 ESTNewsAlpine Immune Sciences Q3 2022 Earnings PreviewN/A
2022-10-27 21:26 ESTNewsAlpine: Ramifications Of The Davoceticept TerminationN/A
2022-10-27 21:25 ESTNewsAlpine Immune Sciences: ALPN-202 May Be Dead, But The Company Isn'tN/A
2022-10-24 18:20 ESTNewsAlpine Immune ends enrollments for cancer studies after patient deathN/A
2022-09-21 04:34 ESTNewsAlpine Immune Sciences drops 13% after hours on $100M stock offeringN/A
2022-09-21 04:34 ESTNewsAlpine Immune Sciences prices $100M stock offeringN/A
2022-08-11 22:35 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.60 misses by $0.21, revenue of $5.29M misses by $4.75MN/A
2022-08-10 12:06 ESTNewsEvotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303N/A
2022-06-08 00:04 ESTNewsAndrew S. Sandler is the new chief medical officer of Alpine ImmuneN/A
2022-05-24 13:14 ESTNewsFDA lifts partial clinical hold on Alpine Immune's davoceticept for malignanciesN/A
2022-05-13 06:49 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.25, revenue of $13.63MN/A
2022-04-25 17:20 ESTNewsAlpine: Rest Before Rallying AgainN/A
2022-03-18 11:15 ESTNewsAlpine Immune Sciences GAAP EPS of -$0.52 misses by $0.22, revenue of $4.53M misses by $9.44MN/A
2022-03-07 15:24 ESTNewsPartial clinical hold placed on Alpine Immune's davoceticept for malignanciesN/A
2021-12-16 22:17 ESTNewsAlpine Immune, Horizon Therapeutics team up to develop therapies for autoimmune and inflammatory diseasesN/A
2021-11-11 00:43 ESTNewsAlpine Immune Sciences EPS misses by $0.56, misses on revenueN/A
2021-09-22 20:46 ESTNewsMRIN, ALPN, SMMT and LPTX among after hours moversN/A
2021-09-17 12:49 ESTNewsAlpine Immune secures $91M through equity offeringN/A
2021-08-12 11:57 ESTNewsAlpine Immune Sciences (ALPN) Investor PresentationN/A
2021-08-11 15:56 ESTNewsAlpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 19:56 ESTNewsAlpine Immune Sciences EPS misses by $0.12, misses on revenueN/A
2021-07-20 18:38 ESTNewsAlpine Immune Sciences files for $150M mixed shelf offeringN/A
2021-07-20 18:35 ESTNewsAlpine Immune Sciences: Better Days AheadN/A
2021-07-20 18:33 ESTNewsAlpine Immune releases promising early data on lupus candidateN/A
2021-07-20 18:22 ESTNewsAlpine Immune shares rise on clinical trial collaboration agreement with MerckN/A
2021-04-16 08:52 ESTNewsAlpine Immune Sciences Is A Blind Buy After The Recent Price DecreaseN/A
2021-03-19 11:35 ESTNewsAlpine Immune Sciences EPS beats by $0.04, beats on revenueN/A
2021-03-19 11:29 ESTNewsAlpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-19 04:07 ESTEarnings EstimateAn EPS average of -$0.86 is estimated for the 2022 year.Sell
2021-03-19 04:07 ESTEarnings EstimateAn EPS average of -$0.27 is estimated for the quarter ending on June 30, 2021.N/A
2021-01-06 02:19 ESTNewsAlpine: Is This A Young Oak Tree?N/A
2020-12-22 19:05 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.5 to $21.4.Neutral
2020-12-13 03:09 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 15:07 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 11:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 11:05 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 20:38 ESTNewsAlpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-13 03:09 ESTEarnings EstimateAn EPS average of -$0.08 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-12 16:24 ESTNewsAlpine Immune Sciences EPS misses by $0.05, misses on revenueN/A
2020-11-01 16:57 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 04:09 ESTFinancialsCompany financials have been released.Neutral
2020-08-22 04:04 ESTFinancialsCompany financials have been released.Neutral

About Alpine Immune Sciences, Inc (ALPN):

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

See Advanced Chart

General

  • Name Alpine Immune Sciences, Inc
  • Symbol ALPN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 53
  • Last Split Factor1:4
  • Last Split Date2017-07-25
  • Fiscal Year EndDecember
  • IPO Date2015-06-17
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.alpineimmunesciences.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 59.37
  • Price/Book (Most Recent Quarter) 4.91
  • Enterprise Value Revenue 46.44
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$0.73
  • Next Year EPS Estimate -$0.86
  • Next Quarter EPS Estimate -$0.26
  • Operating Margin -640%
  • Return on Assets -17%
  • Return on Equity -54%
  • Revenue 4.58 million
  • Earnings Per Share -$2.97
  • Revenue Per Share $0.23
  • Gross Profit -34107000
  • Quarterly Earnings Growth 561.9%
View More

Highlights

  • Market Capitalization 328.72 million
  • EBITDA -48231000
  • Analyst Target Price $21.4
  • Book Value Per Share $2.83
View More

Share Statistics

  • Shares Outstanding 23.8 million
  • Shares Float 8.66 million
  • % Held by Insiders 2849%
  • % Held by Institutions 52.56%
  • Shares Short 385513
  • Shares Short Prior Month 377164
  • Short Ratio 2.78
  • Short % of Float 4%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 1.73
  • 52 Week High $16.37
  • 52 Week Low $2.1
  • 50 Day Moving Average 12.51
  • 200 Day Moving Average 10.57
View More

Dividends

  • Dividend Date 2017-07-25
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Alpine Immune Sciences, Inc (ALPN) Dividend Calendar:

ALPN's last dividend payment was made to shareholders on July 25, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Alpine Immune Sciences, Inc (ALPN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31-$0.27-$0.3112.9%
2020-09-302020-11-12$1.91 million-$0.28-$0.23-20.43%
2020-06-302020-08-11$N/A-$0.53$0.54-199.07%
2020-03-312020-05-14$1.09 million-$0.30-$0.4736.17%
2019-12-312020-03-30$884000-$0.33-$0.5943.59%
2019-09-302019-11-13$289000-$0.62-$0.688.82%
2019-06-302019-08-13$567000-$0.64-$0.685.54%
2019-03-312019-05-09$N/A-$0.70-$0.69-1.45%
2018-12-312019-03-18$705000-$0.80-$0.80-0.25%
2018-09-302018-11-08$-390000-$0.88-$0.57-55.48%
2018-06-302018-08-09$390000-$0.57-$0.43-31.55%
2018-03-312018-05-14$315000-$0.38-$0.403.8%
2017-12-312018-03-28$1.6 million-$0.33-$0.379.59%
2017-09-302017-11-13$128000$0.18-$0.28164.29%
2017-06-302017-09-29$738000-$5.40-$2.19-146.58%
2017-03-312017-05-01$737000-$2.28-$1.90-20%
2016-12-312017-02-13$2.95 million-$2.00-$2.209.09%
2016-09-302016-11-07$N/A-$1.92-$2.3718.99%
2016-06-302016-08-01$N/A-$2.20-$2.09-5.26%
2016-03-312016-05-02$N/A-$2.04-$1.76-15.91%
2015-12-312016-02-29-$1.68-$1.43-17.48%
2015-09-302015-11-02$N/A-$1.56-$1.666.02%
2015-06-302015-08-03$N/A-$1.41-$0.41-243.9%

Alpine Immune Sciences, Inc (ALPN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Alpine Immune Sciences, Inc (ALPN) Chart:

Alpine Immune Sciences, Inc (ALPN) News:

Below you will find a list of latest news for Alpine Immune Sciences, Inc (ALPN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Alpine Immune Sciences, Inc (ALPN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-08-162.50CALL0 0431.67TRUE00
2024-08-1650CALL0 0335.92TRUE00
2024-08-167.50CALL0 0227.81TRUE00
2024-08-16100CALL0 0248.27FALSE00
2024-08-1612.50CALL0 0201FALSE00
2024-08-16150CALL0 0183.78FALSE00
2024-08-1617.512.85CALL0 5140.44FALSE00
2024-08-162045.85CALL0 4142.69FALSE00
2024-08-1622.54.5CALL0 9142.78FALSE00
2024-08-16256.6CALL0 4128.64FALSE00
2024-08-163034.4CALL0 10104.52FALSE00
2024-08-163530.3CALL0 1884.41FALSE00
2024-08-164025CALL0 667.16FALSE00
2024-08-164519.56CALL0 3252.03FALSE00
2024-08-165014.6CALL0 27039.74FALSE00
2024-08-165510CALL0 5690FALSE00
2024-08-16605CALL0 40318.03FALSE00
2024-08-16650.05CALL0 64170FALSE00
2024-08-16700.05CALL0 6460FALSE00
2024-08-16750CALL0 00FALSE00
2024-08-16800CALL0 00FALSE00
2024-08-16850CALL0 00FALSE00
2024-08-16900CALL0 00FALSE00
2024-08-16950CALL0 00FALSE00
2024-08-162.50PUT0 00FALSE00
2024-08-1650.02PUT0 10FALSE00
2024-08-167.50PUT0 00FALSE00
2024-08-16100.05PUT0 70TRUE00
2024-08-1612.50PUT0 00TRUE00
2024-08-16150.42PUT0 50TRUE00
2024-08-1617.50PUT0 00TRUE00
2024-08-16204.7PUT0 100TRUE00
2024-08-1622.51.06PUT0 100TRUE00
2024-08-16251.24PUT0 80TRUE00
2024-08-16300.05PUT0 330TRUE00
2024-08-16350.1PUT0 70TRUE00
2024-08-16400.05PUT0 7040TRUE00
2024-08-16450.1PUT0 1030TRUE00
2024-08-16500.1PUT0 840TRUE00
2024-08-16550.2PUT0 1170TRUE00
2024-08-16600.05PUT0 496110.48TRUE00
2024-08-16650.05PUT0 2191.3TRUE00
2024-08-16705.6PUT0 117.65TRUE00
2024-08-167510.6PUT0 126.28TRUE00
2024-08-16800PUT0 034.19TRUE00
2024-08-16850PUT0 048.89TRUE00
2024-08-16900PUT0 053.51TRUE00
2024-08-16950PUT0 059.78TRUE00
2024-11-152020CALL0 0103.22FALSE00
2024-11-1522.50CALL0 091.13FALSE00
2024-11-152513.5CALL0 080.33FALSE00
2024-11-153035.85CALL0 2761.39FALSE00
2024-11-153512.43CALL0 144.15FALSE00
2024-11-154024.66CALL0 464.6FALSE00
2024-11-154519.6CALL0 651.34FALSE00
2024-11-155014.6CALL0 339.48FALSE00
2024-11-15559.9CALL0 20928.66FALSE00
2024-11-15604.9CALL0 4170FALSE00
2024-11-15650.05CALL0 13340FALSE00
2024-11-15700.05CALL0 680FALSE00
2024-11-15750CALL0 00FALSE00
2024-11-15800.1CALL0 260FALSE00
2024-11-15850CALL0 00FALSE00
2024-11-15900CALL0 00FALSE00
2024-11-15950.15CALL0 100FALSE00
2024-11-15200.05PUT0 300TRUE00
2024-11-1522.50PUT0 00TRUE00
2024-11-15250PUT0 00TRUE00
2024-11-15300.1PUT0 20TRUE00
2024-11-15350PUT0 00TRUE00
2024-11-15400.13PUT0 30TRUE00
2024-11-15450.05PUT0 720TRUE00
2024-11-15500.05PUT0 220TRUE00
2024-11-15550.05PUT0 50TRUE00
2024-11-15600.05PUT0 30700TRUE00
2024-11-15650.05PUT0 7101.32TRUE00
2024-11-15700PUT0 014.3TRUE00
2024-11-15750PUT0 021.02TRUE00
2024-11-15800PUT0 027.15TRUE00
2024-11-15850PUT0 032.6TRUE00
2024-11-15900PUT0 037.52TRUE00
2024-11-15950PUT0 042.06TRUE00

Latest ALPN Trades:

Date Shares Price
Jun 13, 2022 7:57 PM EST19$8.61
Jun 13, 2022 7:57 PM EST6$8.6
Jun 13, 2022 7:57 PM EST100$8.61
Jun 13, 2022 7:59 PM EST15$8.585
Jun 13, 2022 7:59 PM EST1$8.585

Alpine Immune Sciences, Inc (ALPN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018177/0000899243-20-018177-index.htm
2020-07-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626199/000000000020006420/0000000000-20-006420-index.htm
2020-08-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1626199/000000000020007443/0000000000-20-007443-index.htm
2018-04-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318010650/0000899243-18-010650-index.htm
2018-04-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318010652/0000899243-18-010652-index.htm
2018-08-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318021736/0000899243-18-021736-index.htm
2018-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318021737/0000899243-18-021737-index.htm
2018-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924318025713/0000899243-18-025713-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000496/0000899243-19-000496-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000497/0000899243-19-000497-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000498/0000899243-19-000498-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000499/0000899243-19-000499-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000500/0000899243-19-000500-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319000503/0000899243-19-000503-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319001661/0000899243-19-001661-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319001662/0000899243-19-001662-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319001663/0000899243-19-001663-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319003030/0000899243-19-003030-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319003031/0000899243-19-003031-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319003032/0000899243-19-003032-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319003038/0000899243-19-003038-index.htm
2019-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924319015346/0000899243-19-015346-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000637/0000899243-20-000637-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000638/0000899243-20-000638-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000639/0000899243-20-000639-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000640/0000899243-20-000640-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000641/0000899243-20-000641-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000642/0000899243-20-000642-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320000643/0000899243-20-000643-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320002067/0000899243-20-002067-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320002068/0000899243-20-002068-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320002069/0000899243-20-002069-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018172/0000899243-20-018172-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018173/0000899243-20-018173-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018177/0000899243-20-018177-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000089924320018864/0000899243-20-018864-index.htm
2019-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000091957419001006/0000919574-19-001006-index.htm
2019-01-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626199/000092189519000160/0000921895-19-000160-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626199/000092189520000527/0000921895-20-000527-index.htm
2018-01-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000094787118000053/0000947871-18-000053-index.htm
2018-01-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000094787118000060/0000947871-18-000060-index.htm
2019-01-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000094787119000042/0000947871-19-000042-index.htm
2019-01-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000094787119000043/0000947871-19-000043-index.htm
2019-01-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000094787119000044/0000947871-19-000044-index.htm
2020-07-30SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000094787120000655/0000947871-20-000655-index.htm
2019-01-24SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000114420419002677/0001144204-19-002677-index.htm
2018-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518098445/0001193125-18-098445-index.htm
2018-03-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000119312518098624/0001193125-18-098624-index.htm
2018-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626199/000119312518127697/0001193125-18-127697-index.htm
2018-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626199/000119312518127706/0001193125-18-127706-index.htm
2018-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518127833/0001193125-18-127833-index.htm
2018-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518162515/0001193125-18-162515-index.htm
2018-06-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1626199/000119312518189391/0001193125-18-189391-index.htm
2018-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518189404/0001193125-18-189404-index.htm
2018-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518192903/0001193125-18-192903-index.htm
2018-06-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000119312518199598/0001193125-18-199598-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518238992/0001193125-18-238992-index.htm
2018-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312518281909/0001193125-18-281909-index.htm
2019-01-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312519010606/0001193125-19-010606-index.htm
2019-01-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312519012912/0001193125-19-012912-index.htm
2019-01-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312519014154/0001193125-19-014154-index.htm
2019-01-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312519014248/0001193125-19-014248-index.htm
2019-02-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000119312519032222/0001193125-19-032222-index.htm
2020-07-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312520204703/0001193125-20-204703-index.htm
2020-08-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312520206868/0001193125-20-206868-index.htm
2020-08-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119312520206870/0001193125-20-206870-index.htm
2020-08-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1626199/000119312520211999/0001193125-20-211999-index.htm
2018-08-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1626199/000119380518001083/0001193805-18-001083-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119004779/0001209191-19-004779-index.htm
2019-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119004783/0001209191-19-004783-index.htm
2019-01-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119005067/0001209191-19-005067-index.htm
2019-01-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119005068/0001209191-19-005068-index.htm
2019-01-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000120919119005069/0001209191-19-005069-index.htm
2018-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/0001564590-18-006916-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619918000004/0001626199-18-000004-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619918000010/0001626199-18-000010-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619918000012/0001626199-18-000012-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619918000016/0001626199-18-000016-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619918000018/0001626199-18-000018-index.htm
2019-01-30DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000001/0001626199-19-000001-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000007/0001626199-19-000007-index.htm
2019-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000010/0001626199-19-000010-index.htm
2019-03-18S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1626199/000162619919000012/0001626199-19-000012-index.htm
2019-03-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000014/0001626199-19-000014-index.htm
2019-03-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000016/0001626199-19-000016-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000019/0001626199-19-000019-index.htm
2019-04-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000022/0001626199-19-000022-index.htm
2019-04-05424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000024/0001626199-19-000024-index.htm
2019-04-11PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000026/0001626199-19-000026-index.htm
2019-04-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000029/0001626199-19-000029-index.htm
2019-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000034/0001626199-19-000034-index.htm
2019-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000035/0001626199-19-000035-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000038/0001626199-19-000038-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000040/0001626199-19-000040-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000043/0001626199-19-000043-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000046/0001626199-19-000046-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000049/0001626199-19-000049-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000053/0001626199-19-000053-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000055/0001626199-19-000055-index.htm
2019-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000060/0001626199-19-000060-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619919000064/0001626199-19-000064-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619919000067/0001626199-19-000067-index.htm
2020-01-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000003/0001626199-20-000003-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000008/0001626199-20-000008-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1626199/000162619920000009/0001626199-20-000009-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000011/0001626199-20-000011-index.htm
2020-05-05DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000014/0001626199-20-000014-index.htm
2020-05-05DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000015/0001626199-20-000015-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000019/0001626199-20-000019-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619920000020/0001626199-20-000020-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000024/0001626199-20-000024-index.htm
2020-06-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000026/0001626199-20-000026-index.htm
2020-06-188-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000030/0001626199-20-000030-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000031/0001626199-20-000031-index.htm
2020-07-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1626199/000162619920000033/0001626199-20-000033-index.htm
2020-07-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000035/0001626199-20-000035-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000037/0001626199-20-000037-index.htm
2020-08-07DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000038/0001626199-20-000038-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000043/0001626199-20-000043-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1626199/000162619920000045/0001626199-20-000045-index.htm
2020-08-11S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1626199/000162619920000047/0001626199-20-000047-index.htm
2020-08-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1626199/000162619920000049/0001626199-20-000049-index.htm
2020-08-19424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1626199/000162619920000052/0001626199-20-000052-index.htm
2019-04-04EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1626199/999999999519000606/9999999995-19-000606-index.htm
2020-07-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1626199/999999999520001835/9999999995-20-001835-index.htm
2020-08-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1626199/999999999520002196/9999999995-20-002196-index.htm
2019-03-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1626199/999999999719001523/9999999997-19-001523-index.htm
2019-03-29CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1626199/999999999719002103/9999999997-19-002103-index.htm

Alpine Immune Sciences, Inc (ALPN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alpine Immune Sciences, Inc (ALPN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2849%
Institutional Ownership: 5256%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-05-30James Paul RickeySenior VP and CFOBuy10,000.004.9549,500.0010,000.00https://www.sec.gov/Archives/edgar/data/1626199/000089924319015346/0000899243-19-015346-index.htm
2019-02-08MANAGEMENT L.L.C. TIGER10% Share HolderSell25,000.005.85146,245.00137,728.00https://www.sec.gov/Archives/edgar/data/1626199/000091957419001006/0000919574-19-001006-index.htm
2019-01-18Frazier Life Sciences VIII, L.P.10% Share HolderBuy372,439.005.371,999,997.432,571,450.00https://www.sec.gov/Archives/edgar/data/1626199/000120919119004783/0001209191-19-004783-index.htm
2019-01-18James N TopperDirectorBuy372,439.005.371,999,997.432,571,450.00https://www.sec.gov/Archives/edgar/data/1626199/000120919119004779/0001209191-19-004779-index.htm
2020-01-23James Paul RickeySenior VP and CFOBuy18,543.0028,543.00https://www.sec.gov/Archives/edgar/data/1626199/000089924320002069/0000899243-20-002069-index.htm
2019-01-18Xiangmin CuiDirectorBuy3,165,735.005.3716,999,996.953,165,735.00https://www.sec.gov/Archives/edgar/data/1626199/000120919119005069/0001209191-19-005069-index.htm
2020-01-23STANFORD L PENGPresident & Head of R&DBuy32,217.0032,217.00https://www.sec.gov/Archives/edgar/data/1626199/000089924320002068/0000899243-20-002068-index.htm
2019-01-18ORBIMED ADVISORS LLCDirectorBuy372,439.005.371,999,997.433,670,955.00https://www.sec.gov/Archives/edgar/data/1626199/000094787119000043/0000947871-19-000043-index.htm
2019-01-18Peter A. ThompsonDirectorBuy372,439.005.371,999,997.433,670,955.00https://www.sec.gov/Archives/edgar/data/1626199/000094787119000044/0000947871-19-000044-index.htm
2019-01-18Alpine ImmunoSciences, L.P.10% Share HolderBuy190,875.005.371,024,998.753,994,781.00https://www.sec.gov/Archives/edgar/data/1626199/000089924319001663/0000899243-19-001663-index.htm
2019-01-18Jay VenkatesanDirectorBuy190,875.005.371,024,998.753,994,781.00https://www.sec.gov/Archives/edgar/data/1626199/000089924319001661/0000899243-19-001661-index.htm
2019-01-18MITCHELL GOLDExecutive Chairman and CEOBuy190,875.005.371,024,998.753,994,781.00https://www.sec.gov/Archives/edgar/data/1626199/000089924319001662/0000899243-19-001662-index.htm
2020-01-23MITCHELL GOLDExecutive Chairman and CEOBuy67,569.0068,861.00https://www.sec.gov/Archives/edgar/data/1626199/000089924320002067/0000899243-20-002067-index.htm